https://scholars.lib.ntu.edu.tw/handle/123456789/581969
標題: | Asunaprevir-containing regimens for the treatment of hepatitis C virus infection | 作者: | Yang S.-S. JIA-HORNG KAO |
關鍵字: | asunaprevir; direct-acting antivirals; hepatitis C virus; interferon; NS3 protease inhibitor; ribavirin | 公開日期: | 2015 | 出版社: | Expert Reviews Ltd. | 卷: | 9 | 期: | 1 | 起(迄)頁: | 9-20 | 來源出版物: | Expert Review of Gastroenterology and Hepatology | 摘要: | Chronic hepatitis C virus (HCV) infection has been a tremendous health burden worldwide with an annual mortality of 300,000 people due to decompensated cirrhosis or hepatocellular carcinoma. A combination of interferon (IFN), ribavirin (RBV), and/or direct-acting antivirals (DAAs) can eradicate HCV in a various proportion of infected patients. Unfortunately, IFN-based therapy is associated with significant adverse effects, contraindications, and limited tolerability, leading to lower adherence or even treatment discontinuation. With the rapid evolution of newer DAAs or host-targeting agents, emerging HCV therapy is moving towards an IFN- and RBV-free strategy. To this end, a recently developed NS3 protease inhibitor, asunaprevir (ASV), in combination with other DAAs as IFN/RBV-containing or -free regimen, has shown promising results with fewer adverse effects. In this review, preclinical profiles and clinical proof-of-concept studies of ASV, including viral resistance, host polymorphism, and role of ASV in future HCV therapy are reviewed and discussed. ? 2015 Informa UK, Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84918810280&doi=10.1586%2f17474124.2014.953930&partnerID=40&md5=30de1ef5b0593d7452062ca8b5a748cf https://scholars.lib.ntu.edu.tw/handle/123456789/581969 |
ISSN: | 1747-4124 | DOI: | 10.1586/17474124.2014.953930 | SDG/關鍵字: | alpha interferon; aminotransferase; asunaprevir; beclabuvir; bms 605339; ciluprevir; daclatasvir; nonstructural protein 3; nonstructural protein 4A; peginterferon alpha; peginterferon alpha2a; placebo; ribavirin; serine proteinase inhibitor; telaprevir; unclassified drug; antivirus agent; asunaprevir; isoquinoline derivative; NS3 protein, hepatitis C virus; proteinase inhibitor; sulfonamide; virus protein; antiviral activity; antiviral resistance; Article; asthenia; cardiovascular disease; diarrhea; drug disposition; drug dose reduction; drug exposure; drug fatality; drug liver level; drug potentiation; drug safety; drug structure; drug synthesis; drug tolerability; drug treatment failure; drug withdrawal; fatigue; fever; gastrointestinal symptom; genetic polymorphism; headache; hepatitis C; Hepatitis C virus; human; hyperbilirubinemia; liver cirrhosis; multiple drug dose; nausea; neutropenia; nonhuman; protein function; rhinopharyngitis; side effect; single drug dose; structure activity relation; unspecified side effect; virus inhibition; virus mutant; virus replication; animal; antagonists and inhibitors; drug combination; drug development; drug effects; enzymology; genetics; growth, development and aging; Hepacivirus; Hepatitis C, Chronic; metabolism; molecularly targeted therapy; treatment outcome; virology; Animals; Antiviral Agents; Drug Discovery; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Isoquinolines; Molecular Targeted Therapy; Protease Inhibitors; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Virus Replication |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。